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Objectives: To evaluate the effectiveness of multidisciplinary 
foot-care, and to evaluate the methodological considerations 
of a trial of multidisciplinary care in juvenile idiopathic ar-
thritis.
Design: Exploratory randomised controlled trial.
Subjects/Patients: Children/adolescents with juvenile idio-
pathic arthritis and inflammatory joint disease affecting the 
foot/ankle.
Methods: Standard medical care was compared with a 12 
month program of multidisciplinary foot-care informed 
by musculoskeletal ultrasound. This program was centred 
on strict disease control through rigorous examination and 
interventions delivered by a team comprised of a paediat-
ric rheumatologist, podiatrist, physiotherapist and muscu-
loskeletal ultrasonographer. Patients were assessed on foot 
impairment and disability scores using the Juvenile Arthritis 
Foot Disability Index. 
Results: Forty-four participants, aged 3–17 years were ran-
domly assigned to receive the experimental (n = 21) or usual 
care (n = 23) interventions. There was an overall improve-
ment in levels of foot related impairments in both groups 
over 12 months. Between-group differences in change scores 
for the Juvenile Arthritis Foot Disability Index were not sta-
tistically significant at 6 or 12 month follow-ups. 
Conclusion: The integrated multidisciplinary foot care in-
terventions described in this trial were safe, but did not 
improve foot impairment levels relative to usual care. This 
trial identified several methodological challenges including 
recruitment/retention, difficulties with outcome tools and 
potential confounders. 
Key words: juvenile idiopathic arthritis; foot; physiotherapy; 
podiatry.
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is the commonest rheumatic 
disorder of childhood and a leading cause of paediatric acquired 
disability with a UK wide prevalence estimated at 0.65–2 per 
1,000 children (1). Foot impairments and disability persist in 
over 60% of children who have JIA despite recent improve-
ments in its medical management (2). Synovitis and peri-artic-
ular manifestations such as tenosynovitis and enthesitis have 
been associated with pain, reduced joint ranges-of-motion, 
deformity, gait abnormalities, fatigue and poor functional 
status (3–6). Radiographic imaging studies demonstrate that 
erosive changes occur early, and there appears to be a small 
therapeutic ‘window of opportunity’ to prevent permanent dam-
age and poor functional outcomes through pharmacological 
and rehabilitative interventions (7–8). Moreover, recent studies 
employing musculoskeletal ultrasound (MSUS) demonstrate 
that subclinical signs of inflammation are common in the foot 
and ankle even in those who meet clinical remission criteria 
(9, 10). Subclinical inflammation has also been associated with 
continued structural deterioration in adults with rheumatoid 
arthritis (RA) (11).
Clinical practice guidelines recommend multidisciplinary 
care for children/adolescents with JIA (12). There is emerging 
evidence that a multi-disciplinary team (MDT) approach to 
care may be effective in rheumatology settings (13). However, 
few studies have evaluated the efficacy of foot specific inter-
ventions in the MDT setting (14–17). Image-guided locally 
administered intra-articular cortico-steroid injections (ICIs) 
appear to be more efficacious than blindly administered ICIs 
at eliminating signs of synovial hypertrophy (14–16). How-
ever, only one randomised trial has evaluated the efficacy of 
custom-made foot orthoses (FOs) in JIA and demonstrated 
improvements in pain and functional ability levels (17). 
To provide optimum foot care, it is essential that disease 
activity, early joint destruction, and functional status be 
monitored (13). As such a new paradigm of foot care has been 
proposed (13); taking on board contemporary issues such as 
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early detection, targeted therapy and tight control. This not only 
includes standard treatments for joint dysfunction such as FOs 
and exercise programs, but extended scope practice including 
MSUS assessments, and MSUS-guided ICIs. Accordingly the 
aims of this study were to 1) evaluate the clinical effective-
ness of an integrated multi-disciplinary foot care program for 
patients with JIA and 2)investigate the key methodological 
considerations for a two-arm non-pharmacological explora-
tory parallel trial of an integrated multidisciplinary foot care 
program versus ‘usual care’.
MATERIAlS AND METHODS
Eligibility
Children and adolescents with a definitive diagnosis of JIA according 
to the International league of Associations for Rheumatology (IlAR) 
who were being treated at the Royal Hospital for Sick Children. glas-
gow, UK between March 2008 and March 2010, were eligible for inclu-
sion (18). Children/adolescents with JIA were included if they satisfied 
at least one of the following: previously documented arthritis in the 
foot including small joints derived from medical case notes, previously 
documented foot arthritis in one or more large joints (tib-talar/subtalar) 
derived from medical case notes, or current widespread polyarthritis 
involving large and small foot joints derived from clinical examina-
tion by a consultant paediatric rheumatologist. Children/adolescents 
who were in receipt of podiatric care at the time of enrolment were 
also eligible for inclusion. Patients with an unconfirmed diagnosis of 
JIA, and/or only upper limb, jaw, or neck involvement were excluded. 
The glasgow west local Research Ethics Committee granted ethical 
approval (Ref 06/S0703129). written informed consent was obtained 
from participants and parents/guardians in accordance with the Dec-
laration of Helsinki. This trial was registered with the International 
Standard Randomised Controlled Trial Number (ISRCTN) register 
(registration number ISRCTN49672274).
Assessments
At baseline all participants were assessed to ensure they satisfied the 
inclusion criteria. Demographic and disease characteristic data includ-
ing age, gender, body mass index (BMI), disease sub-type, date of 
diagnosis, disease duration were recorded. BMI scores were converted 
to BMI standard deviation scores using standard methods (19). All 
baseline assessments and outcome measures were recorded prior to 
randomization. The medical care plan formulated by the paediatric 
rheumatologist (JgM/RDS) was documented prior to randomisation. 
Baseline assessment of disease activity was conducted by the pae-
diatric rheumatologist (JgM/RDS) accompanied by a physiotherapist 
(MB/lF) using 5 of the 6 American College of Rheumatology (ACR) 
Core variables for JIA, a validated group of core clinical outcome 
variables for disease activity (20). This core set includes active/limited 
joint counts (0–77), functional ability assessment via the Childhood 
Health Assessment Questionnaire (CHAQ), and visual analogue scales 
(vAS) completed by the physician for global assessment of disease 
activity, and parent/patient for global assessment of well-being (20, 
21). Erythrocyte sedimentation rate (ESR) was omitted as blood sam-
ples were not routinely collected from each participant. 
participants underwent examinations of their foot and ankle joints to 
assess for tenderness and swelling by a podiatrist (gJH/Jw). Clinical 
features were recorded as present/absent and summated to derive tender 
and swollen foot joint counts (tibiotalar, subtalar, calcaneo-cuboid, 
talo-navicular, 5 metatarsophalangeal, 4 proximal interphalangeal, 5 
distal interphalangeal) providing a total score (0–36). Five tendons 
(tibialis posterior, flexor digitorum longus, flexor hallucis longus, 
peroneus brevis, and peroneus longus) and 3 miscellaneous soft tis-
sues (Achilles tendon insertion [TA], plantar fascia origin [pF], and 
retrocalcaneal bursa [RCB]) were assessed for tenderness and/or swell-
ing. Clinical features were recorded as present/absent summated to 
derive tender and swollen miscellaneous soft tissue site counts (0–16 
total score). Tenderness and swelling were determined according to 
the EUlAR handbook of standard methods (22). Foot deformity was 
assessed according to the Structural Index (SI) to provide summated 
scores for rearfoot/ankle (0–14) and forefoot (0–24) (23). 
MSUS was undertaken by an experience sonographer (DET) using 
established methodologies for the foot and ankle employing B-mode 
and colour and power Doppler (24). These same sites were assessed 
independently for effusion, synovial hypertrophy (SH), erosion, and 
power Doppler signal (pD) (joints); tendons for grey scale features 
of fluid and PD within the tendon sheath; the TA and PF for abnormal 
thickening, and RCB for effusion. Standardised definitions for ultra-
sound derived pathology were employed throughout (25). Imaging 
was conducted using a Siemens Acuson Antares machine (Malvern, 
USA) with 14l5 (5–13MHz, footprint size 45 mm × 9 mm) probe, 
or Esaote Mylab 25 gold (genova, Italy) with lA435 (18–16MHz) 
probe (footprint size 40 mm × 10 mm). US features were recorded as 
present/absent and summated for a total score for joints (0–28) and 
soft tissues (0–16).
Outcomes
The primary outcome was assessed at baseline, 6 months and 12 
months. The primary outcome employed in this study was the Juve-
nile Arthritis Foot Disability Index (JAFI), a 27 item questionnaire 
organised by 3 dimensions related to impairment, activity limitation 
and participation restriction (26). Each item is scored on a 5-point 
likert scale, which describes the frequency of foot-related problems 
experienced in the previous week (0 = never, 1 = less than once a 
week, 2 = once a week, 3 = 2 or 3 times a week, 4 = always), and a 
median score is calculated for each dimension. The JAFI has been 
shown to be valid and reliable for assessing foot-related disability in 
JIA (26). Following the recommendations from Andre et al. (26), the 
JAFI was completed by parents/guardians of children < 10 years and 
self-completed by adolescents ≥ 10 years of age. Secondary outcomes 
collected at 12 months from baseline were:
• functional impairment using the CHAQ, a valid and reliable instru-
ment for measuring global functional status in children with JIA (21)
• self- and proxy-reported health-related quality of life (HRQoL) using 
the EQ-5D-y (patients) and EQ-5D-3l (parents/guardians) question-
naires, which are both comparable, valid and reliable generic measures 
of HRQol in children/adolescents and adults (27, 28)
• disease activity using the ACR core variables for JIA (minus ESR) 
(20)
• localised foot disease activity using summated clinical examination 
indices of tenderness and swelling (22)
• foot deformity score using the SI (23)
• localised foot disease activity using summated MSUS examination 
indices of effusion, SH, erosion, and PD modified from Szkudlarek 
et al. (24).
Randomization
Treatment allocation was conducted by minimisation, a highly effec-
tive method of allocation that is recommended for use in randomised 
controlled trials (29). Treatment allocation by minimisation depends 
upon the characteristics of participants already enrolled to ‘minimise’ 
the influence of confounding factors (30). Minimisation was adopted 
to achieve balance between groups according to age, gender, and base-
line score from the JAFI impairment domain (primary outcome). This 
method was conducted by the same researcher throughout the study 
(gJH) using the Minim software package (31). At baseline, the outcome 
of allocation was concealed from all assessing clinicians until clinical 
data were documented. Following minimisation, assessing clinician 
findings remained undisclosed for those participants allocated to the 
usual care arm. Throughout the trial, usual care arm clinicians were 
blinded to participants’ inclusion to ensure normal practice remained 
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so. participants and trial personnel were not blinded to the outcome 
of allocation. 
Proposed interventions
According to the Medical Research Council (MRC) framework for 
trials of complex interventions, non-pharmacological phase II trials 
allow for the monitoring and modelling of interventions (32). The in-
tended experimental and ‘usual care’ interventions are described below.
Multidisciplinary foot care intervention
Following clinical assessments and MSUS identification of inflammation, 
a plan of appropriate clinical care was to be devised by the paediatric 
rheumatologist (JgM/RDS), the podiatrist (Jw/gJH), the sonographer 
(DET/RDS) and physiotherapist (MB/lF). ICIs prescribed by the rheu-
matologists (JgM/RDS) were to be conducted under general anaesthesia 
using MSUS guidance ideally within 4 weeks (13–15). participants were 
to receive individualised care packages comprising combinations of FOs 
and targeted home exercise programs for symptomatic joints including 
stretching and muscle strengthening (16, 33). The multidisciplinary foot 
care intervention was delivered exclusively by the trial personnel. Cus-
tomised FOs were to be manufactured via an external laboratory (Firefly 
Orthoses, Sligo, Ireland) and distributed within 2 weeks. 
Usual care 
In the absence of standard practice guidelines for foot care in JIA, 
usual care was recorded over the course of the trial. participants 
randomised to the usual care arm were to receive normal outpatient 
medical care from their consultant paediatric rheumatologists, who 
remained blinded to all other clinical assessments. Usual care arm 
clinicians were not simultaneously involved in the medical care of 
intervention arm participants. Further referrals to podiatry for care 
delivered by the usual care arm podiatrist (gFw) were permitted from 
the usual care paediatric rheumatologists. Clinical care and referrals 
were monitored and recorded to define the experimental intervention 
and usual care (see Results). 
Adverse events procedure
In the event of any minor adverse reaction or side effects due to any 
interventions these were to be documented and reported to the trial steer-
ing committee and formally reviewed for action at 6-monthly meetings. 
In the event of any major adverse events experienced by trial partici-
pants, it was the chief investigator‘s responsibility to report the major 
adverse event to the study sponsor and the trial steering committee.
Statistical methods
Based on clinical estimates obtained from a previous pilot study incor-
porating the JAFI as an outcome measure, sample size was calculated 
for the analysis to have 90% power of detecting a 1 point reduction 
in the JAFI impairment domain score over 6 months of intervention 
at 5% significance (2). A minimum of forty-four patients (22 in each 
trial arm) were required, and subsequently a sample size of 60 (30 in 
each arm) was targeted to account for potential loss-to-follow-up (34).
Statistical analyses were conducted via the SpSS 18.0 (SpSS Inc. 
Chicago, Il, USA). Demographic and disease characteristics data were 
described using standard descriptive statistics. The primary analysis 
compared the change in JAFI scores for each dimension between the 
intervention and control group at 6 months from baseline. A Mann-
whitney U test was used to analyse the primary outcome variable 
where the distributions of change scores were skewed and therefore not 
normally distributed (Kolmogorov-Smirnov test, p < 0.05). Two-tailed 
tests were used for all analyses and α was set at 0.05.
longitudinal JAFI scores at 0, 6 and 12 months were analysed 
using repeated measures Friedman’s ANOVA to identify significant 
differences between time points within each group. Distributions of 
change scores from baseline to 12 months follow up for all secondary 
outcomes were not normally distributed and were analysed across 
treatment groups using the Mann-whitney U test. 
For missing data identified at the end of the study, a sensitivity 
analysis was performed in order to identify the most appropriate 
method to address this problem. 
RESUlTS
One-hundred and twenty-six patients attending the paediatric 
rheumatology outpatient clinic were identified as potential 
participants. Forty-one patients refused to participate, and 41 
patients did not meet the trial participant inclusion criteria 
(Fig. 1). Forty-four patients were allocated by minimisation 
to the experimental intervention arm (n = 21) and the usual 
care (control) arm (n = 23). In the intervention arm all patients 
initially received the intervention until 6 months follow up, 
where one participant declined to participate further due to 
the burden of multiple appointments. In the control arm all 
patients received normal standard care for the duration of the 
trial. Twenty-one participants allocated to receive the inter-
vention completed the primary outcome measure at 6 and 12 
months from baseline. Twenty-three participants allocated to 
the control arm completed the primary outcome measure at 
6 months from baseline. Three were lost to final 12 months 
follow up therefore only 20 patients completed the primary 
outcome and were included for final analysis.
Baseline data
Baseline results are given in Table I. Both treatment groups 
were similar in terms of age, gender and BMI. There were no 
differences between groups for the JAFI impairment domain. 
No significant differences were observed between groups for 
JAFI activity limitation and participation restriction domain 
scores, indices of foot deformity, clinical and US examinations 
of foot disease activity. Similarly, no significant differences 
were observed between group medians for disease duration, 
Fig. 1. Trial profile, recruitment/retention, and participant flow.
Assessed for 
eligibility (n=126) 
  Excluded (n=82) 
  Not meeting inclusion criteria (n=41) 
  Refused to participate (n= 41) 
  Other reasons (n= 0) 
Analyzed  (n=21) 
Excluded from analysis (n=0) 
6 months: Lost to follow-up (n=0)    
Allocated to multidisciplinary foot care 
intervention (n=21) 
Received allocated intervention (n=20) 
Did not receive allocated intervention 
(n=1, declined to participate further 
after 6 months of intervention due to 
burden of appointments) 
12 months: Lost to follow-up (n=3, did 
not complete and return primary 
outcome measure questionnaire) 
Discontinued intervention (n=0) 
Allocated to usual care intervention 
(n=23) 
Received allocated intervention (n=23) 
Did not receive allocated intervention 
(n=0)    
Analyzed  (n=20) 






















12 months: Lost to follow-up (n=0) 
Discontinued intervention (n=1)    
6 months: Lost to follow-up (n=0)    
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CHAQ score, vAS pain and general wellbeing, in the direction 
of worse scores in the intervention group. Indices of joint dis-
ease activity and limitation were slightly higher in the control 
group. Both self- and proxy- reported quality of life outcomes 
were similar. Differences in baseline characteristics between 
groups did not reach statistical significance (independent t test/
Mann-whitney U, p > 0.05). Treatment groups were similar 
in terms of pharmacological management. There were small 
differences in proportions of JIA disease subtypes. 
Actual multidisciplinary foot care interventions delivered over 
12 months
participants had separate consultations with a paediatric rheu-
matologist, podiatrist, physiotherapist and sonographer at base-
Table I. Baseline characteristics of the study participants
Characteristic





Age, years, mean (SD) 10.1 (4.22) 10.0 (3.39)
Male/female, n 7/14 6/17
Body mass index, mean (SD) 18.90 (4.38) 19.34 (3.93)
SDS body mass index percentiles, mean (SD) 62 (0.3) 67 (0.3)
Foot impairments and disability
JAFI impairment, median (range) 2 (0–4) 2 (0–4)
JAFI activity limitation, median (range) 2 (0–3.5) 1.5 (0–3)
JAFI participation restriction, median (range) 1 (0–3.5) 2 (0–3)
Structural index foot deformity score (0–38), median (range) 5 (0–17) 6.5 (0–16)
Structural index rearfoot deformity score (0–14), median (range) 4 (0–10) 4.5 (0–10)
Structural index forefoot deformity score (0–24), median (range) 0 (0–7) 2 (0–8)
Tender foot joints (0–38), median (range) 2 (0–23) 1 (0–17)
Swollen foot joints (0–38), median (range) 1 (0–19) 0 (0–17)
Tender misc soft tissues (0–16), median (range) 0 (0–6) 0 (0–14)
Swollen misc soft tissues (0–16), median (range) 0 (0–6) 0 (0–5)
US effusions (0–28), median (range) 3 (0–10) 2 (0–18)
US synovial hypertrophy (0–28), median (range) 1 (0–6) 1 (0–8)
US erosions (0–28), median (range) 0 (0–2) 0 (0–8)
US power Doppler signal (0–28), median (range) 0 (0–3) 0 (0–8)
US tenosynovitis (0–5), median (range) 0 (0–2) 0 (0–2)
US power Doppler signal tendon sheaths (0–5), median (range) 0 (0–2) 0 (0–2)
Condition
Disease duration, years, mean (SD) 3.74 (2.65) 4.06 (3.33)
CHAQ (0–3), median (range) 0.625 (0–1.5) 0.875 (0–2.125)
vAS pain (0–100), median (range) 33 (2–81) 41 (0–92)
vAS gen (0–100), median (range) 26 (0–57) 37 (0–72)
Active joints (0–77), median (range) 3 (0–20) 0 (0–40)
limited joints (0–77), median (range) 3.5 (0–17) 1 (0–22)
Self EQ-5D utility index, mean (SD) 0.57 (0.31) 0.58 (0.35)
Self EQ-5D vAS (0–100), mean (SD) 69.37 (16.83) 75.09 (21.71)
proxy EQ-5D utility index, mean (SD) 0.69 (0.29) 0.60 (0.33)
proxy EQ-5D vAS (0–100), mean (SD) 76.89 (17.38) 73.38 (18.64)
pharmacological management
Analgesics, n (%) 2 (9) 3 (13)
NSAIDs, n (%) 2 (9) 3 (13)
Methotrexate, n (%) 18 (86) 16 (70)
Etanercept, n (%) 7 (33) 5 (22)
Sulphasalazine, n (%) 1 (5) 0 (0)
Rituximab, n (%) 0 (0) 1 (4)
Combination methotrexate & etanercept, n (%) 5 (24) 5 (22)
Disease subtypes
persistent oligo, n (%) 7 (33) 4 (17)
Extended oligo, n (%) 4 (19) 5 (22)
poly–, n (%) 6 (29) 10 (43)
poly+, n (%) 0 (0) 2 (9)
psA, n (%) 2 (10) 1 (4)
ERA, n (%) 2 (10) 0 (0)
Systemic, n (%) 0 (0) 0 (0)
Undifferentiated, n (%) 0 (0) 1 (4)
SD: standard deviation; JAFI: Juvenile Arthritis Foot Disability Index; SDS: standardised deviation score British 1990 growth reference (UK 90); 
NSAID: non-steroidal anti-inflammatory drugs; poly–: polyarthritis rheumatoid factor negative; poly+: polyarthritis rheumatoid factor positive; PsA: 
psoriatic arthritis; ERA; enthesitis related arthritis.
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line, and 3, 6, 9 and 12 months follow ups. All participants were 
advised regarding basic foot care, footwear, targeted exercises 
and basic joint protection. podiatric intervention was centred 
on orthotic therapy. Of the 21 participants 17 were prescribed 
FOs that were designed on a case-by-case basis. All FOs were 
manufactured from a subtalar-joint-neutral plaster-of-paris cast 
using semi-rigid carbon fibre (TL2100 2.2 mm) for the orthotic 
shell, 3 mm poron/vinyl for cushioning/top cover extended to 
the toes, and posted to calcaneal vertical position. Additions 
were made on a case-by-case basis and included: 1 unilateral 
14 mm heel raise (for leg length discrepancy), 2 bilateral me-
dial flanges (for severe pes planovalgus foot posture), and 2 
bilateral metatarsal bars (for correctable lesser toe deformities). 
During the manufacture process, 11 of 17 participants received 
pre-fabricated FOs for the interim period. Four participants 
received silicone splints for lesser-toe deformities. Thirteen of 
21 participants received MSUS-guided ICIs in the joints and/or 
soft tissues of the foot and ankle. Triamcinolone Hexacetonide 
(TH) was administered by the same paediatric rheumatologist 
(JgM) assisted by the same sonographer (DET) throughout. 
Eight of 17 ICIs took place under general anaesthetic more 
than 4 weeks after originally planned due to limited theatre 
availability. Over the 12 months of the trial, 10 patients were 
started on new medications (4 etanercept, 2 infliximab, 2 oral 
prednisilone, 1 methotrexate, 1 adalimumab); 6 participants 
had their dosages escalated (5 methotrexate, 1 etanercept); and 
9 of 21 patients received stable medication over the 12 months 
duration of the trial. 
Actual usual care delivered over 12 months
Of the 23 participants allocated to the usual care arm, 5 re-
ceived a referral from the paediatric rheumatologist to the 
standard care arm podiatrist (gFw). Of these participants 3 
received FOs on a case-by-case basis. Seven of the 23 partici-
pants received blindly administered ICIs (TH) within 4 weeks. 
Over 12 months 18 of 23 control participants received stable 
systemic medications. Of those not receiving stable medication, 
1 received an escalated dose (methotrexate), and 4 patients 
were started on new medications (methotrexate, adalimumab, 
adalimumab + infliximab, infliximab).
Table II. Primary outcome measure: differences between groups for 








Baseline 21 2 (0 to 2) 23 2 (0 to 3) 0.807, ns
∆ 6 months 21 0 (–1 to 0.5) 23 0 (–1 to 0) 0.976, ns
∆ 12 months 21 0 (0 to 0.5) 19 0 (–1 to 0) 0.358, ns
JAFIal
Baseline 21 2 (0.25 to 2) 23 1.5 (0 to 2) 0.480, ns
∆ 6 months 21 0 (–0.5 to 0.5) 23 0 (–0.5 to 0.5) 0.683, ns
∆ 12 months 21 0 (–0.5 to 1) 19 0 (–0.5 to 1) 0.607, ns
JAFIpr
Baseline 21 1 (0 to 2.25) 23 2 (0 to 2.5) 0.753, ns
∆ 6 months 21 0 (–0.5 to 0.5) 23 0 (–0.5 to 0.5) 0.698, ns
∆ 12 months 21 0 (–0.5 to 1) 19 0 (–0.5 to 0.5) 0.995, ns
aMann-whitney test of change scores intervention arm vs change scores 
control arm.
∆ differences between 6 months and baseline scores (6 months – baseline 
scores) and 12 months and baseline scores (12 months score – baseline 
score), negative scores indicate an improvement, positive scores indicate 
a deterioration, score of 0 indicates no change.
JAFIimp: Juvenile Arthritis Foot Disability Index impairment; JAFIal: 
JAFI activity limitation; JAFIpr: JAFI participation restriction; IQR: 
interquartile range.
Fig. 2. A; JAFI impairment change scores (0–6 months), and B; longitudinal JAFI impairment scores in each group.
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Primary outcome data
Descriptive data for the JAFI dimension scores for each group 
at each time point, as well as change scores between each time 
point are presented in Table II and Fig. 2. For changes in the 
JAFI impairment score (Fig. 2) the intervention group did 
not differ significantly from the control group (median = 0) 
following 6 months of multidisciplinary foot care (U = 240.0, 
z = –0.037, p = 0.976, r = –0.006). Similarly, changes in JAFI 
activity limitation and participation scores in the interven-
tion group did not differ significantly from the control group 
(U = 224.5, z = –0.418, p = 0.683, r = –0.06 and U = 225.0, 
z = –0.398, p = 0.698, r = –0.06 respectively). longitudinal 
JAFI scores for foot related impairment did not significantly 
change over the course of the trial in either the interven-
tion group (χ2 (2) = 0.76, p = 0.724) or the control group (χ2 
(2) = 1.61, p = 0.462). 
Secondary outcome data: disability, health-related quality of 
life and local foot impairments
Secondary outcome data with comparisons between groups 
are presented in Tables III and IV. There were no significant 
differences between treatment groups for secondary outcomes 
at final follow up. In terms of adverse events, one participant 
did not tolerate FOs due to inadequate shoe space. 
DISCUSSION
This trial was designed to conform to the MRC framework for 
trials of complex interventions, which recommends that trial re-
search be conducted according to a continuum of evidence based 
upon the quality of existing preliminary evidence (32). This 
design permitted the gathering of valuable information regard-
ing feasibility, which could be used to inform future trials (35). 
Integrated multidisciplinary foot care did not result in a 
significant reduction in disease-related foot impairments and 
disability. Both the treatment groups appeared to improve by 
one point on the JAFI impairment scale between baseline and 
12 months follow up, however, the differences between groups 
for change scores did not reach statistical significance. Long 
disease durations, and moderate levels of foot impairment and 
rearfoot deformity scores were detected at baseline. There is 
significant evidence which demonstrates that greater functional 
improvements are more achievable with second-line drugs in 
patients with early RA as opposed to those with established 
disease (36). Furthermore, van der leeden et al. (37) recently 
demonstrated that earlier intervention with customised foot 
orthoses was predictive of improved foot pain and disability 
outcomes in patients with RA. Therefore residual disease char-
acteristics in the present study may have resulted in a decreased 
likelihood for participants to improve (2, 6).





Median (IQR) pa U-statistic Z-score Effect size
CHAQ
Baseline 18 0.63 (0.22 to 1.03) 21 0.88 (0.5 to 1.5)
∆ 12 months 21 0 (–0.41 to 0.06) 23 0 (–0.06 to 0.06) 0.558, NS 169 –0.6 –0.09
vAS pain
Baseline 17 33 (14.5 to 51) 21 41 (9 to 69)
∆ 12 months 21 0 (–3.5 to 16) 23 0 (0 to 10.5) 0.959, NS 176.5 –0.06 –0.09
vAS well-being
Baseline 14 26 (11.25 to 48.75) 21 37 (13 to 49)
∆ 12 months 21 0 (–17.25 to 8.5) 23 0 (–6 to 7) 0.522, NS 128 –0.657 –0.11
Active joints
Baseline 18 3 (1 to 6.5) 22 0 (0 to 7.5)
∆ 12 months 21 –1.5 (–4.25 to 0) 23 0 (–2.5 to 0) 0.165, NS 151 –1.4 –0.22
limited joints
Baseline 18 3.5 (1.5 to 8.25) 23 1 (0 to 6)
∆ 12 months 21 –2 (–4.75 to 0) 23 0 (–1.5 to 0.25) 0.128, NS 142.5 –1.532 –0.24
EQ-5D U selfb
Baseline 19 0.62 (0.52 to 0.76) 21 0.66 (0.52 to 0.75)
∆ 12 months 21 0 (–0.1 to 0.01) 23 0 (–0.04 to 0.04) 0.973, NS 199 –0.014 –0.022
EQ-5D vAS selfb
Baseline 19 65 (54 to 85) 21 75 (60 to 96)
∆ 12 months 21 0 (–10 to 20) 23 0 (–7.5 to 0) 0.342, NS 165.6 –0.966 –0.153
EQ-5D U proxyb
Baseline 19 0.69 (0.58 to 1) 21 0.62 (0.55 to 0.82)
∆ 12 months 21 0 (0 to 0.11) 23 0 (0 to 0.1) 0.539, NS 176.5 –0.627 –0.099
EQ-5D vAS proxyb 
Baseline 19 80 (60 to 90) 21 70 (55 to 95)
∆ 12 months 21 0 (–1 to 14) 23 0 (0 to 15) 0.325, NS 183 –0.473 –0.074
aMann-whitney U test of change scores intervention arm vs change scores control arm. 
∆ differences between 12 months and baseline scores (12 months score – baseline score), negative scores indicate an improvement, positive scores 
indicate a deterioration (unless otherwise state withb).
IQR: interquartile range; CHAQ: Childhood Health Assessment Questionnaire; vAS: visual analogue scale. Effect sizes: 0.1 = small, 0.3 = medium, 
0.5 = large.
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The experimental intervention was based upon an early dis-
ease detection model coupled with tight control (13). This was 
centred on early detection of signs of new inflammation in the 
form of synovitis in those already diagnosed with JIA, in order 
to develop and implement a personalised multidisciplinary 
care plan. Aggressive systemic pharmacological management 
involving escalating dosages and/or advancement to anti-tumor 
necrosis factor or T-cell modulating therapies did not appear to 
improve levels of foot impairments levels in the intervention 
arm participants. This was surprising as short- and long-term 
benefits of such therapies are well documented (38). However, 
actual medical care delivered in both groups did not appear to 
differ significantly over 12 months. This suggests that the lack of 
any significant difference in primary outcome change scores may 
have been a result of many patients having received second-line 
systemic pharmacological therapy before and during the trial. 
Evidence from systematic reviews suggests that customised 
foot orthoses are sustainably effective in reducing painful foot 
symptoms and disability in patients with RA (39). The positive 
effects of foot orthoses for reducing pain and image-guided 
ICIs for reducing synovial hypertrophy in JIA were not dem-
onstrated at follow-up in this study (14,17). The longer-term 
benefits from integrated multi-disciplinary care may not have 
been detectable within a 12 month period. previous studies in 
RA have demonstrated significant and sustainable reductions 
in foot related disability levels at follow up after 30 months 
of orthotic therapy (40). Indeed, Powell et al.’s (17) findings 
were from a study of JIA patients with disease durations of 2 





Median (IQR) pa U-statistic Z-score Effect size
SI foot
Baseline 21 5 (2 to 7) 22 6.5 (3.5 to 12)
∆ 12 months 21 0 (–1 to 2.5) 23 0 (–5.25 to 0) 0.304, NS 189.5 –1.042 –0.16
SI rearfoot
Baseline 21 4 (1 to 6) 22 4.5 (2 to 8)
∆ 12 months 21 0 (–2 to 2) 23 0 (–4 to 0.25) 0.574, NS 208 –0.575 –0.09
SI forefoot
Baseline 21 0 (0 to 3) 22 2 (0 to 5.25)
∆ 12 months 21 0 (0 to 1) 23 0 (–0.5 to 0) 0.173, NS 180.5 –1.42 0.213
Tender joints
Baseline 21 2 (0 to 7.5) 23 1 (0 to 5)
∆ 12 months 21 0 (–1 to 0) 23 0 (0 to 0) 0.496, NS 220.5 –0.672 –0.101
Swollen joints
Baseline 21 0 (0 to 5) 23 0 (0 to 4)
∆ 12 months 21 0 (0 to 0) 23 0 (–1 to 0) 0.486, NS 220.5 –0.672 0.101
Tender soft tissues
Baseline 21 0 (0 to 2) 23 0 (0 to 2)
∆ 12 months 21 0 (0 to 0) 23 0 (0 to 0) 0.749, NS 231 –0.388 0.058
Swollen soft tissues
Baseline 21 0 (0 to 1.5) 23 0 (0 to 1)
∆ 12 months 21 0 (0 to 0) 23 0 (0 to 0) 0.781, NS 231 –0.448 0.073
US effusions
Baseline 19 3 (0 to 6) 15 0 (0 to 4)
∆ 12 months 19 0 (–3 to 3) 15 0 (–3 to 0) 0.414, NS 119 –0.835 –0.143
US synovitis
Baseline 19 1 (0 to 3) 15 0 (0 to 2)
∆ 12 months 19 0 (–2 to 0) 15 0 (–2 to 0) 0.331, NS 115 –0.992 –0.17
US erosions
Baseline 19 0 (0 to 0) 15 0 (0 to 0)
∆ 12 months 19 0 (0 to 0) 15 0 (0 to 0) 0.944, NS 142 –0.026 –0.004
US pDS
Baseline 19 0 (0 to 1) 15 0 (0 to 1)
∆ 12 months 19 0 (0 to 0) 15 0 (–1 to 0) 0.807, NS 136 –0.28 –0.048
US soft tissues fluid
Baseline 19 0 (0 to 0) 15 0 (0 to 0)
∆ 12months 19 0 (0 to 0) 15 0 (0 to 0) 0.727, NS 134.5 –0.358 –0.061
US soft tissue pDS
Baseline 19 0 (0 to 0) 15 0 (0 to 0)
∆ 12 months 19 0 (0 to 0) 15 0 (0 to 0) 0.220, NS 114.5 –1.462 –0.25
aMann-whitney U test of change scores intervention arm vs change scores control arm.
∆ differences between 12 months and baseline scores (12 months score – baseline score), negative scores indicate an improvement, positive scores 
indicate a deterioration.
SI: structural index; pDS: power Doppler Signal; IQR: interquartile range. Effect sizes: 0.1 = small, 0.3 = medium, 0.5 = large.
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years or less, with final follow up at 3 months from baseline. 
Furthermore, ICIs are considered to be effective in the short-
term but long-term beneficial effects have not been established 
(14). participants enrolled in this study typically had estab-
lished disease (> 3 years disease duration) and therefore did 
not receive interventions early.
The use of MSUS to inform systemic therapy was a con-
temporary feature of this trial. Several researchers recommend 
image guidance for administering ICIs particularly for joints 
of the rearfoot as a result of several positive responses in 
recent studies (14–16). An important issue arising from the 
use of MSUS to inform care in this trial was that US findings 
appeared to influence clinical decision making as more ICIs 
were administered in the intervention group. Similar findings 
in adult rheumatology clinical practice have been reported (41). 
Further investigation is required to determine the prognostic 
value of US informed therapeutic decision making.
Several limitations of this study merit further attention. The 
desired number of study participants outlined a priori was not 
achieved therefore the analysis was statistically underpowered 
(34). Therefore the analysis may have been vulnerable to 
type II error. Recruitment and retention of participants was 
challenging as many parents of potential participants were 
reluctant to commit to additional appointments. This resulted 
in the exclusion of a significant proportion of eligible patients 
(n = 41, 32% of patients assessed for eligibility). Furthermore, 
recruitment resulted in a heterogeneous sample. This led to dif-
ficulties with standardisation of treatments, a well-recognised 
problem associated with complex interventions (42). An addi-
tional problem experienced during the trial was the prevalence 
of missing and/or incomplete data, particularly for secondary 
outcome measures data. Missing data is a common and ever-
present problem in randomized controlled trials and several 
methods have been proposed and implemented to combat this 
problem (43). The method adopted to address missing data 
in this trial was the last-observation-carried-forward (lOCF) 
method, where missing values are imputed by the participant’s 
last available observations. lOCF is based on the assump-
tion that outcome remains constant at the last observed value 
after drop-out/loss to follow-up. This is considered to be an 
unlikely outcome for many clinical trials (44). However, a 
sensitivity analysis was conducted on the original trial data 
sets plus several new data sets that were developed according 
to the use of various missing-data-imputation methods (lOCF, 
mean value imputation, maximum value imputation, minimum 
value imputation, and random value imputation). The aim of 
this analysis was to explore the magnitudes of differences in 
change scores between groups to determine which would be 
the most conservative method. lOCF was found to be the 
most conservative method while being less labour intensive, 
thus it was subsequently used to impute all missing data at 
final follow-up. 
The trial was vulnerable to bias where participants and care 
providers were not blinded to the outcome of allocation. The 
nature of the study dictated that those in the intervention arm 
would be removed from their regular programs of outpatient 
care. Therefore elimination of patient and/or care provider’s 
expectations and/or preferences regarding treatments and 
outcomes was not possible and so the trial was vulnerable 
to response bias. Allocation concealment and blinding is 
acknowledged as being more difficult to achieve in trials of 
non-pharmacological and complex interventions and often 
relies upon complex methods (42). This trial may also have 
been vulnerable to intervention choice bias where the time of 
intervention delivery, and the complexity of the intervention in-
cluding many facets, may have led to type II error regarding the 
clinical effectiveness of the experimental intervention. while 
the process of minimisation employed would have reduced 
the vulnerability to selection biases, the exploratory nature of 
the trial restricted the potential for allocation concealment and 
blinding amongst trial personnel. Therefore ascertainment bias 
could have been a potential confounding factor as personnel 
delivering interventions and recording assessments were aware 
of participants’ allocations. 
The results of this study suggest that sensitivity and respon-
siveness of the primary outcome measure for detecting change 
in foot impairments and disability outcomes may be limited. 
For example 12/44 participants scored 0 for impairment at 
baseline but only 2/12 had no positive responses. This finding 
suggests that foot related disability may be underestimated by 
the JAFI due to a significant floor effect. Similar problems have 
been observed in RA where the Foot Impact Scale (FIS), a well 
validated questionnaire with good psychometric qualities, ap-
parently lacks responsiveness to conventional podiatry care (35). 
The use of the SI, a tool specifically developed for use in 
adults with RA has not been validated for use in children with 
JIA. Since the completion of this trial an alternative measure 
of foot deformity/posture known as the foot posture index 
(FpI) has been shown to be highly reliable for use in children 
(45–46). As yet the FpI has not been used to measure foot 
posture in children with JIA, but it may be a promising tool for 
evaluation in future studies. At present there is no normative 
paediatric data available for the SI, however it has shown good 
face validity in previous studies in JIA (2). In addition, it may 
be more suitable for measuring children with JIA compared 
to the FpI as it also includes a scale for forefoot deformity.
Integrated multi-disciplinary foot care with the use of MSUS 
is a logical intervention designed to address disease-related 
foot problems in JIA. The results of this study suggest that 
this model of care is no more effective than current usual care 
offered through the National Health Service, which for the most 
part comprises medical management without image-guidance 
or podiatric therapies. These results should be carefully con-
sidered in the context of the study limitations, the exploratory 
nature of the trial, and the heterogeneity of the study sample 
participants. Moreover, this was a single-centre study and 
results may not be generalisable. This trial successfully 
identified several useful areas for the development of future 
trials by highlighting sources of bias, procedural problems, 
and limitations of the primary outcome measure. Overall the 
experimental intervention was safe with few reports of intoler-
ance to treatment or adverse events. 
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